{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-26-002252","form_type":"8-K","ticker":"QTZM","cik":"0001663038","company_name":"Quantum Genesis AI Corp.","filed_at":"2026-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.693992+00:00","generated_at":"2026-05-15T06:07:27.295026+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Quantum Genesis AI confirms CEO assignment of ibuprofen synthesis patent","bullets":["CEO Naveen Kulkarni assigned all rights in US Patent App. US20250146029A1 for enzymatic ibuprofen synthesis to the company.","Assignment effective as of Nov. 2, 2023, formalizing a prior 2023 Asset Purchase Agreement.","Company will amend FY2025 10-K and FY2026 Q1 & Q2 10-Qs to update IP disclosures.","No new consideration; agreement confirms existing ownership."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-26-002252","json":"https://secwatch.observer/filing/0001477932-26-002252.json","markdown":"https://secwatch.observer/filing/0001477932-26-002252.md","text":"https://secwatch.observer/filing/0001477932-26-002252.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1663038/000147793226002252/0001477932-26-002252-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1663038/000147793226002252/qtzm_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:07:27.295026+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b2134c66af41984660c5e29b30215624ba617933","claim":"Quantum Genesis AI Corp. entered into Intellectual Property Assignment Agreement with Naveen Kulkarni (effective 2026-04-09).","evidence_excerpt":"On April 9, 2026, Quantum Genesis AI Corp. (the “Company”) entered into a confirmatory Intellectual Property Assignment Agreement (the “Assignment Agreement”) with Naveen Kulkarni, the Company’s Chief Executive Officer (the “Assignor”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1663038/000147793226002252/0001477932-26-002252-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Naveen Kulkarni"},{"label":"Effective","value":"2026-04-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}